Study summary
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP8374 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumor malignancies. Also primary purpose is to characterize the pharmacokinetic profile of ASP8374 when administered as a single agent and in combination with pembrolizumab. Last primary purpose of this study is to determine the recommended Phase 2 dose (RP2D) of ASP8374 when administered as a single agent and in combination with pembrolizumab.
The secondary purpose of this study is to evaluate the anti-tumor effect (objective response rate [ORR], duration of response [DOR], persistence of response after discontinuation, and disease control rate [DCR]) of ASP8374 when administered as a single agent and in combination with pembrolizumab.
NTP: Neutropenia
NHAE:Non-haematological AE
GBS: Guillain-Barré syndrome""
IRR: Infusion-related reaction
AST: Aspartate aminotransferase
ALT: Alanine aminotransferase
MS/MG: Myasthenia Syndrome/Myasthenia Gravis
TRT: Treatment-related Toxicity
TCP: Thrombocytopenia
Study documents
Get more information
Would you like more information about clinical trial sites that are recruiting participants for A multiple-dose study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors? Contact us by filling out your information to the right and we’ll respond to you.
Locations
Frequently Asked Questions
While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.
Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.
In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.
Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.
Explore More



For Your Information
THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE